ESR1 and breast cancer: Furthermore, miR-221 and miR-222 promote proliferation by targeting cell cycle regulators such as p27Kip1 and estrogen receptor alpha (ERα), with their upregulation correlating with increased invasiveness and poor prognosis in breast cancer patients (64).